Global Cancer Photodynamic Therapy Market, By Multiple Cancer Treatments (Non-Melanoma Skin Cancer, Prostate Cancer, Breast Cancer, Brain Tumor, Lung Cancer, Head and Neck Cancer, Oral Lesions and Oesophageal Cancer, Cervical Cancer, Colorectal Cancer and Cancer of the Bile Duct and the Pancreas), Product (Photosensitizer Drug and Photodynamic Therapy Devices), End User (Hospitals, Cancer Treatment Centers and Others) – Industry Trends and Forecast to 2031.
Cancer Photodynamic Therapy Market Analysis and Size
Cancer photodynamic therapy (PDT) has a non-invasive nature, distinguished from traditional cancer treatments such as surgery, chemotherapy, or radiation therapy. PDT involves the administration of a photosensitizing agent, which selectively accumulates in cancer cells. Its targeted approach minimizes the need for invasive procedures, reduces the risk of complications, and enhances patient comfort and recovery, making PDT an attractive option for patients seeking less invasive cancer treatments.
Global cancer photodynamic therapy market size was valued at USD 3.76 billion in 2023 and is projected to reach USD 5.25 billion by 2031, with a CAGR of 4.25% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024-2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Multiple Cancer Treatments (Non-Melanoma Skin Cancer, Prostate Cancer, Breast Cancer, Brain Tumor, Lung Cancer, Head and Neck Cancer, Oral Lesions and Oesophageal Cancer, Cervical Cancer, Colorectal Cancer, and Cancer of the Bile Duct and the Pancreas), Product (Photosensitizer Drug and Photodynamic Therapy Devices), End User (Hospitals, Cancer Treatment Centers and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina and rest of South America
|
|
Market Players Covered
|
Theralase Technologies Inc.(Canada), Biofrontera AG (Germany), Hologic, Inc. (U.S.), Bausch + Lomb.(Canada), Quest PharmaTech Inc. (Canada), LUMIBIRD (France), Galderma S.A. (Switzerland), Modulight, Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), SUS Advancing Technology Co., Ltd. (Japan), Novartis AG (Switzerland), Allergan Plc (Ireland), Valeant Pharmaceuticals International (Canada), Dr. Reddy’s Laboratories Ltd (India), Bedford Laboratories (U.S.), Fresenius Kabi AG (Germany), Zydus Pharmaceuticals, Inc. (India), Mayne Pharma Group Limited (Australia), Glenmark Pharmaceuticals (India)
|
|
Market Opportunities
|
|
Market Definition
Cancer photodynamic therapy (PDT) is a treatment that uses a photosensitizing agent and light to target and destroy cancer cells. The photosensitizer is activated by specific wavelengths of light, generating reactive oxygen species that kill the cancer cells while minimizing damage to surrounding healthy tissue.
Cancer Photodynamic Therapy Market Dynamics
Drivers
- High Demand for Cancer Photodynamic Therapy due to Increased Incidence of Cancer
With cancer rates on the ascent, there is an escalating demand for effective and less invasive treatment options such as PDT. This demand is particularly pronounced as patients seek therapies with reduced side effects and improved outcomes. PDT's minimally invasive nature and potential for outpatient treatment make it an attractive option amidst the increasing burden of cancer. Consequently, the growing prevalence of cancer fuels both the adoption of PDT by healthcare providers and investment in PDT research and development by pharmaceutical companies, contributing to market expansion.
- Increased Technological Advancements Enhances Cancer Photodynamic Therapy
Technological advancements encompass improvements in light sources, photosensitizers, and delivery systems, enhancing treatment efficacy and safety. Innovations such as targeted PDT, using specific molecules to selectively target cancer cells, are reducing off-target effects and improving outcomes. Additionally, advancements in imaging technologies enable better localization of tumors, optimizing PDT precision. Integration with other treatment modalities, such as immunotherapy and targeted therapy, further enhances therapeutic efficacy, making PDT a promising option in the oncology landscape.
Opportunities
- Expansion of Cancer Photodynamic Therapy Due to Personalized Approaches
PDT's ability to selectively target cancer cells while sparing healthy tissue aligns with the principles of personalized medicine, ensuring precise and targeted therapy. This customized approach enhances treatment efficacy, minimizes side effects, and improves patient outcomes, driving the integration of PDT into personalized cancer care paradigms. As research continues to uncover biomarkers and therapeutic targets, PDT's adaptability and precision will further propel its adoption as a personalized cancer treatment modality.
- Impact of Regulatory Environment on Adoption of Cancer Photodynamic Therapy
Regulatory agencies such as the FDA and EMA evaluate the safety and efficacy of PDT technologies and indications, providing guidelines for market approval and usage. Compliance with regulatory requirements is essential for market entry and commercialization of PDT products. Clear regulatory pathways facilitate innovation and market growth by providing companies with a framework for development and commercialization. Changes in regulations, such as expanded indications or streamlined approval processes, can significantly impact market dynamics and investment decisions within the cancer PDT market. Therefore, staying abreast of regulatory updates is essential for market participants to navigate effectively.
Restraints/Challenges
- High Development Costs Limit the Adoption of Cancer Photodynamic Therapy
PDT requires substantial investment in research and development to advance photosensitizer compounds, light sources, and delivery systems. These costs include preclinical studies, clinical trials, and regulatory approvals, contributing to the overall expense of bringing PDT products to market. These high development costs may discourage investment from smaller companies and limit the number of players entering the market, potentially slowing down innovation and market growth in the long term.
- High Complexity limits the Demand for Cancer Photodynamic Therapy
PDT requires specialized equipment, trained personnel, and specific protocols for effective administration. This complexity can limit the availability of PDT in healthcare settings, particularly in resource-constrained regions or facilities lacking the necessary infrastructure. The need for precise light delivery and photosensitizer activation further adds to the technical challenges of PDT. As a result, the widespread implementation of PDT may be hindered, impacting its uptake and market penetration compared to more accessible treatment modalities.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In August 2022, Asieris Pharmaceuticals reached a milestone as its multinational Phase III Clinical Trial of Cevira (APRICITY) concluded enrollment. Cevira represents a novel non-surgical approach to treating cervical high-grade squamous intraepithelial lesions (HSIL). This breakthrough therapy combines a photosensitizer that accumulates in target cells with a drug-device combination product, promising significant advancements in cervical lesion management
- In March 2022, Biofrontera Inc. achieved a significant regulatory milestone with the inclusion of the previously granted U.S. patent No. 11,235,169 for the BF-RhodoLED XL illumination device in the U.S. Food and Drug Administration (FDA) publication 'Approved Drug Products with Therapeutic Equivalence Evaluations,' commonly referred to as the Orange Book. This recognition underscores the device's importance and paves the way for its widespread utilization in photodynamic therapy applications
Cancer Photodynamic Therapy Market Scope
The market is segmented on the basis of multiple cancer treatments, product, and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them in making strategic decisions for the identification of core market applications.
Multiple Cancer Treatments
- Non-Melanoma Skin Cancer
- Prostate Cancer
- Breast Cancer
- Brain Tumor
- Lung Cancer
- Head and Neck Cancer
- Oral Lesions
- Oesophageal Cancer
- Cervical Cancer
- Colorectal Cancer
- Cancer of the Bile Duct the Pancreas
Product
- Photosensitizer Drug
- Photodynamic Therapy Devices
End User
- Hospitals
- Cancer Treatment Centers
- Others
Cancer Photodynamic Therapy Market Regional Analysis/Insights
The market is analysed and market size insights and trends are provided by multiple cancer treatments, product and end user as referenced above.
The countries covered in the market report are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina and rest of South America.
North America dominance in the market is attributed to its advanced healthcare infrastructure, facilitating better access to cutting-edge treatments. Additionally, the region's significant investments in research and development enhance the innovation and efficacy of photodynamic therapy techniques, fostering market growth. These factors position North America to lead in advancements and adoption of cancer photodynamic therapy, driving expansion throughout the forecast period.
Asia-Pacific is expected to substantially expand in the cancer photodynamic therapy market, which is primarily driven by a growing healthcare infrastructure. Government initiatives are expected to play a pivotal role in accelerating this growth trajectory and fostering advancements in cancer treatment technologies. As healthcare access improves and awareness increases, the region stands to witness a notable surge in demand for photodynamic therapy solutions, positioning it as a key growth market in the coming years.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.
Competitive Landscape and Cancer Photodynamic Therapy Market Analysis
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Some of the major players operating in the market are:
- Theralase Technologies Inc.(Canada)
- Biofrontera AG (Germany)
- Hologic, Inc. (U.S.)
- Bausch + Lomb.(Canada)
- Quest PharmaTech Inc. (Canada)
- LUMIBIRD (France)
- Galderma S.A. (Switzerland)
- Modulight, Inc. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- SUS Advancing Technology Co., Ltd. (Japan)
- Novartis AG (Switzerland)
- Allergan Plc (Ireland)
- Valeant Pharmaceuticals International (Canada)
- Dr. Reddy’s Laboratories Ltd (India)
- Bedford Laboratories (U.S.)
- Fresenius Kabi AG (Germany)
- Zydus Pharmaceuticals, Inc. (India)
- Mayne Pharma Group Limited (Australia)
- Glenmark Pharmaceuticals (India)
SKU-